EUVIMEDDescoperă EUVIMED
EUVIMED · CrossrefJournal

Annals of Oncology

ISSN 0923-7534 · Elsevier BV

Latest articles

  1. 2RO Retrospective exploratory biomarker (BM) analyses from evERA breast cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting

    S.M. Tolaney, J. Liang, W. Darbonne, E. Mayer, M. Martin, G.A. Vidal, L. Moscetti, K. Jhaveri, A.M. Brufsky, W.J. Gradishar, A. Schneeweiss, J.A. O'Shaughnessy, M. Dieterich, L. Lam, T. Fernando, H.S. Rugo

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.011

  2. 3RO 18F-FES PET–defined whole-body ER heterogeneity identifies endocrine responsiveness and predicts survival in ER+/HER2− metastatic breast cancer (MBC): Results of a prospective international clinical trial

    A. Gennari, S. Nardin, E.G.C. Brain, A. Piccardo, A. De Censi, M. Lambertini, F. Matteucci, R. Wuerstlein, R. Seban, F. Fiz, B. Ruffilli, D. Corradengo, G.M. Sacchetti, V. Fontana, O. Nanni, M. Palleschi, V. Rossi, F. D'Avanzo, L. Boni, N. Harbeck

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.012

  3. 13P Sacituzumab govitecan in heavily pretreated and elderly patients with metastatic triple-negative breast cancer: A real-world multicentre study

    M. Kubeczko, A.Z. Konieczna, M. Pieniazek, J. Zubrowska, M. Holanek, R. Soumarova, H. Studentova, M. Malejcikova, K. Winsko-Szczęsnowicz, M. Lisik-Habib, D. Krejci, J. Sustr, I. Kolárová, I. Danielewicz, L. Rusinova, A. Polakiewicz-Gilowska, R. Pacholczak-Madej, M. Jarzab, Z. Bielcikova, M. Puskulluoglu

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.022

  4. 16P Clinical characteristics and outcomes of endocrine-resistant hormone receptor positive, HER2-negative (HR+/HER2−) advanced breast cancer: Insights from the AGO-B CAPTOR trial

    T. Decker, H. Huebner, A.D. Hartkopf, H-C. Kolberg, M.A.M. Thill, J.C. Radosa, B. Lex, N. Ditsch, K. Luedtke-Heckenkamp, M. Van Mackelenbergh, C. Schem, P. Kreis, A. Schneeweiss, W. Janni, T.N. Fehm, V. Mueller, M. Banys- Paluchowski, G. Heinrich, P.A.A. Fasching, M. Schmidt

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.025

  5. 17P Final long-term outcomes of palbociclib-fulvestrant vs. placebo-fulvestrant in HR+/HER2‒ endocrine-sensitive advanced breast cancer: GEICAM/2014-12 (FLIPPER) phase II trial

    J. Albanell, M.T.M. Martinez, L. de la Cruz Merino, M. O'Connor, A.M. Santaballa Bertran, N. Martinez, F. Moreno Anton, I. Fernandez, J.D. Alarcon, J.A. Virizuela Echaburu, J. De la Haba Rodriguez, P. Sanchez-Rovira, L. Gonzalez-Cortijo, I. González Maeso, J.A. Guerra Martínez, M. Ruiz Borrego, C. Bueno Muiño, M. Casas, S. Bezares Montes, F. Rojo

    Published: 2026-12DOI: 10.1016/j.annonc.2026.08.026

Volumes

2026 · 6,2182025 · 5,4172024 · 4,0812023 · 4,2972022 · 4,1692021 · 3,5592020 · 3,7712019 · 4,8272018 · 4,1002017 · 4,4342016 · 4,4432015 · 2,8282014 · 3,0172013 · 1,6382012 · 3,6772011 · 6822010 · 7522009 · 5872008 · 7882007 · 6592006 · 6912005 · 6102004 · 4962003 · 4402002 · 5282001 · 6822000 · 6611999 · 7921998 · 5881997 · 5641996 · 5671995 · 4261994 · 5201993 · 4181992 · 4631991 · 3441990 · 197

Cunoștințe potrivite muncii dumneavoastră.

De la începutul gratuit și cercetarea bibliografică personală până la Research Suite complet.

Vezi tarifele →

Sunt incluse toate textele integrale ale editorilor?

Nu. Referințele bibliografice, rezumatele și textele integrale sunt conținuturi diferite. Disponibilitatea unui text integral depinde de sursă, de Open Access și de licențele pe care le aveți deja. Un abonament EUVIMED nu înlocuiește drepturile suplimentare ale editorilor.